MARKET

COGT

COGT

Cogent Biosciences Inc
NASDAQ
39.99
-0.25
-0.62%
After Hours: 40.00 +0.01 +0.03% 18:12 12/16 EST
OPEN
39.82
PREV CLOSE
40.24
HIGH
41.08
LOW
39.37
VOLUME
2.54M
TURNOVER
--
52 WEEK HIGH
43.73
52 WEEK LOW
3.720
MARKET CAP
6.41B
P/E (TTM)
-22.6380
1D
5D
1M
3M
1Y
5Y
1D
Analysts’ Top Healthcare Picks: Cogent Biosciences (COGT), Novan (NOVN)
TipRanks · 20h ago
Cogent Biosciences: Time For A Pause
Seeking Alpha · 1d ago
Will Bezuclastinib’s Broad APEX and SUMMIT Success Change Cogent Biosciences' (COGT) Narrative?
Simply Wall St · 1d ago
Weekly Report: what happened at COGT last week (1208-1212)?
Weekly Report · 1d ago
Cogent Biosciences (COGT): Valuation Check After Positive APEX Part 2 Trial Results for Bezuclastinib
Simply Wall St · 12/09 14:22
Guggenheim Sticks to Their Buy Rating for Cogent Biosciences (COGT)
TipRanks · 12/09 12:25
Cogent Biosciences Reports Positive Clinical Trial Results
TipRanks · 12/08 21:34
Cogent Biosciences price target raised to $48 from $45 at Jefferies
TipRanks · 12/08 16:05
More
About COGT
Cogent Biosciences, Inc. is a biotechnology company. The Company is focused on developing precision therapies for genetically defined diseases. The Company’s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Kα. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.

Webull offers Cogent Biosciences Inc stock information, including NASDAQ: COGT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, COGT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading COGT stock methods without spending real money on the virtual paper trading platform.